Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GNR 084

Next Previous
Drug Profile

GNR 084

Alternative Names: CD3/CD19 bispecific antibody - GENERIUM Pharmaceuticals/IONTAS; GNR-084

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GENERIUM Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action CD19 antigen inhibitors; CD3 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 15 Oct 2020 Phase-I/II clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) in Russia (IV) (NCT04601584)
  • 19 Dec 2019 GNR 084 is available for licensing as of 19 Dec 2019. http://www.generium.ru/en/
  • 09 Dec 2019 Generium received approval from Russian Health Authorities to initiate the Clinical trial for the treatment of Precursor B-cell lymphoblastic leukaemia lymphoma in Russia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top